# A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents

> **NCT01161524** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 133 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Perampanel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01161524
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2013-06
- **Final completion:** 2014-11
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2019-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01161524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01161524, "A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01161524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*